Labcorp Reaffirms 2026 Outlook, Unveils 5-8% Revenue Growth Target Through 2029
LH sits 32% above its 52-week low of $244.52.
Summary
Labcorp reaffirmed its full-year 2026 adjusted EPS guidance of $18.10-$18.55 and revenue of $14.71B-$14.83B, matching the range issued on July 30. The new information is the long-term outlook: management projects revenue CAGR of 5-8% and adjusted EPS CAGR of 8.5-12% through 2029, implying sustained above-market growth. The company cited specialty testing (oncology, neurology, autoimmune, women's health), personalized health solutions, and AI/robotics as key drivers. This follows the July 30 guidance raise and the September 8 MLM Medical Labs acquisition, reinforcing the growth narrative. The Investor Day presentation today provides the platform for these targets, which are more specific than prior disclosures.
At the time of this announcement, LH was trading at $322.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $244.52 to $341.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.